A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: 125I Seed Implantation Plus Apatinib After Surgery | Zendy

Yiqi Niu | Zendy; Zheng Ding | Zendy; Xianzhao Deng | Zendy; Bomin Guo | Zendy; Jie Kang | Zendy; Bo Wu | Zendy; Youben Fan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: 125I Seed Implantation Plus Apatinib After Surgery

Author(s) -

Yiqi Niu,

Zheng Ding,

Xianzhao Deng,

Bomin Guo,

Jie Kang,

Bo Wu,

Youben Fan

Publication year - 2020

Publication title -

frontiers in endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.518

H-Index - 68

ISSN - 1664-2392

DOI - 10.3389/fendo.2020.00207

Subject(s) - apatinib , medicine , anaplastic thyroid cancer , malignancy , thyroid , cancer , thyroid cancer , oncology , breast cancer , anaplastic carcinoma , surgery

Anaplastic thyroid cancer is known to be the most lethal malignancy among endocrine tumors for its extremely limited survival rate after diagnosis. As a result of this poor survival prognosis, multimodal therapy is currently under investigation to address this global concern. In this reported case, the 125 I seed implantation and vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor apatinib were co-applied to treat a 49-year-old woman with anaplastic thyroid cancer. After the patient began apatinib administration and underwent 125 I seed implantation twice, the tumor size shrank successfully. After a follow-up of 13 months since the initial diagnosis of anaplastic thyroid cancer, the patient survived with a stable disease pathology. In conclusion, this study supports 125 I seed implantation and apatinib as effective therapeutic alternatives for inoperable anaplastic thyroid cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research